Allergan to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

DUBLIN, May 9, 2019 /PRNewswire/ -- Allergan plc AGN today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada. The presentation will begin at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time) on Tuesday, May 14, 2019.

The presentation will be webcast live and can be accessed on Allergan's Investor Relations website at https://www.allergan.com/investors/events-presentations. The webcast can also be accessed through the following URL: https://www.veracast.com/webcasts/baml/healthcare2019/id45106198658.cfm

An archived version will be available following the live presentation and can be accessed at the same location for 90 days.

About Allergan plc

Allergan plc AGN, headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

CONTACTS:      

Allergan:

Investors:
Manisha Narasimhan, PhD
(862) 261-7162

Christine Chiou
(862) 261-7396

Media:  
Amy Rose
(862) 289-3072

Lisa Brown
(862) 261-7320

SOURCE Allergan plc